NLX-266

NLX-266 is a biased agonist of the serotonin 5-HT 1A receptor.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

NLX-266 is a biased agonist of the serotonin 5-HT 1A receptor. It acts specifically as a very-high-affinity and selective ERK1/2-biased serotonin 5-HT 1A receptor agonist (K i = 0.0447 nM; = 0.437 nM; = 94%), with selectivity for ERK1/2 signaling over multiple other pathways.

The drug produces antidepressant- and antiparkinsonian-like effects in rodents, with much greater efficacy than certain other serotonin 5-HT 1A receptor agonists like buspirone and gepirone. It shows favorable pharmacokinetics in rodents. The chemical synthesis of NLX-266 has been described.

NLX-266 was developed by Neurolixis. It was first described in the scientific literature in 2025.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1336845770 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.